Enterococcus spp. (Enteroadherent - Neonatal Diarrhea)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence; Negligible: Little or no market disruption when disease occurs on one or more farms; High risk: Resistance to antibacterial or antiviral treatments is, or can be expected to be a common problem; Moderate risk: Antibacterial or antiviral treatments are commonly used for treating affected individuals; Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations; No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
Criteria Levels
- Foodborne Zoonotic Transmission: No foodborne transmission
- Non-Foodborne Zoonotic Transmission: No non-foodborne zoonotic transmission
- Beyond-Farm Spread Potential: Contained by standard biosecurity
- Detection Difficulty: Moderate detection requiring specialized testing
- Financial Impact - Mortality and Morbidity Costs: Manageable ongoing losses
- Financial Impact - Prevention and Control Costs: Little market disruption
- Antimicrobial Resistance - Pathogen Risk: Elevated AMR requiring vigilant monitoring
- Antimicrobial Resistance - Treatment Impact: Moderate AMR concern from disease management
- Treatment Availability: Effective treatments usually available
- Vaccine Availability: No effective vaccine
- Eradication Feasibility: Not feasible to eradicate
Detailed Justification
1. Foodborne Zoonotic Transmission
Level: No foodborne transmission
Enteroadherent enterococci causing piglet diarrhea are not associated with foodborne zoonotic disease. While enterococci as a genus can be found in food products, the specific enteroadherent strains causing neonatal porcine diarrhea (primarily E. durans, E. villorum, E. hirae) are not recognized foodborne pathogens. The chapter makes no mention of any foodborne human health concern.
2. Non-Foodborne Zoonotic Transmission
Level: No non-foodborne zoonotic transmission
The chapter does not identify any zoonotic potential for enteroadherent enterococci causing piglet diarrhea. These are commensal organisms that cause opportunistic disease in neonatal pigs. No occupational or contact-based human infections from these specific strains are described.
3. Beyond-Farm Spread Potential
Level: Contained by standard biosecurity
Enterococci are ubiquitous commensal organisms: - "Enterococcus spp. are gram-positive cocci known as normal commensal intestinal flora" - Disease requires specific conditions (enteroadherent strains, susceptible neonates)
The organisms are already present in most swine environments. Disease is not spread between farms in the conventional sense - rather, conditions on individual farms may favor clinical expression. Standard biosecurity prevents introduction of specific virulent strains, though the general organism is ubiquitous.
4. Detection Difficulty
Level: Moderate detection requiring specialized testing
Diagnosis is complicated by the commensal nature of enterococci: - "Its presence in healthy piglets confounds the importance of Enterococcus isolation from the intestinal tract" - Both diarrheic (44%) and control pigs (43%) commonly harbor E. hirae
Definitive diagnosis requires histopathology: - "Diagnosis requires a combination of clinical signs, characteristic microscopic lesions, and bacterial culture results" - "Histologically, many gram-positive cocci are adhered to the apical surface of villus enterocytes through the jejunum and ileum"
Simply culturing enterococci is insufficient - characteristic histologic lesions (enteroadherence to villus epithelium) must be demonstrated. This requires more than routine diagnostics.
5. Financial Impact - Mortality and Morbidity Costs
Level: Manageable ongoing losses
The disease represents an ongoing cause of neonatal diarrhea: - "Cases of enteroadherent Enterococcus-associated diarrhea have been reported in piglets between approximately 2 and 20 days of age and appear to be of increasing significance as a cause of porcine neonatal diarrhea since first described" - Retrospective study found "E. hirae was the second most frequently isolated pathogen, detected in 43.4% of cases" - Involved in "New Neonatal Porcine Diarrhea Syndrome (NNPDS)"
The condition causes ongoing losses in affected herds but is manageable and not catastrophic. It represents one of several causes of neonatal diarrhea requiring attention.
6. Financial Impact - Prevention and Control Costs
Level: Little market disruption
Enterococcal diarrhea is not a regulated disease and has no trade implications. There are no slaughter surveillance programs, export restrictions, or market access issues. The financial impact is limited to direct production losses from morbidity and mortality in affected litters.
7. Antimicrobial Resistance - Pathogen Risk
Level: Elevated AMR requiring vigilant monitoring
Enterococci as a genus are notable AMR reservoirs: - "Because of the natural resistance of enterococci to some antibacterial agents, antimicrobial susceptibility testing is advised before treatment" - Enterococci possess known virulence and resistance factors
The chapter specifically acknowledges intrinsic resistance in enterococci. While not elaborated in detail for swine isolates, enterococci are well-recognized as important AMR reservoirs in human medicine (VRE). The potential for resistance genes to transfer between swine and human strains warrants vigilance.
8. Antimicrobial Resistance - Treatment Impact
Level: Moderate AMR concern from disease management
Treatment of neonatal diarrhea often involves empirical antimicrobial use: - "Antimicrobial susceptibility testing is advised before treatment" - implying treatment is common - The syndrome affects young piglets where injectable treatment is standard
Treatment of neonatal diarrhea contributes to antimicrobial selection pressure, though the disease is not treated with mass medication programs. The moderate concern reflects routine treatment of clinical cases.
9. Treatment Availability
Level: Effective treatments usually available
Specific treatment guidance is limited, but response to appropriate antibiotics is implied: - "Antimicrobial susceptibility testing is advised before treatment"
Intrinsic resistance limits some options but does not preclude effective treatment: - Enterococci have predictable susceptibility patterns to certain drug classes - Susceptibility testing enables appropriate drug selection
Treatment is usually effective when appropriate antibiotics are selected based on susceptibility results.
10. Vaccine Availability
Level: No effective vaccine
No vaccine for enteroadherent enterococcal diarrhea is mentioned. Prevention relies on management and sanitation: - "Sanitation between farrowings is presumed helpful in prevention" - "Due to the lack of knowledge about the clinical and epidemiological aspects of this infection, other preventive measures are difficult to recommend"
11. Eradication Feasibility
Level: Not feasible to eradicate
Enterococci are ubiquitous commensals: - "Known as normal commensal intestinal flora" - Present in both healthy and diseased piglets at similar rates
Eradication of normal flora is neither possible nor desirable. The goal is to manage conditions that favor clinical disease expression rather than eliminate the organism.
Summary
Enteroadherent Enterococcus spp. (primarily E. hirae, E. durans, E. villorum) represent an emerging cause of neonatal porcine diarrhea of increasing recognition. These commensal organisms become pathogenic under certain conditions, causing acute watery diarrhea in 2-20 day old piglets. Diagnosis is challenging because enterococci are present in both healthy and affected pigs - characteristic histologic lesions showing bacterial adherence to villus enterocytes are required for definitive diagnosis. The disease causes ongoing but manageable losses with no market disruption. AMR is a concern given the intrinsic resistance patterns of enterococci and their recognized role as resistance reservoirs. No vaccine exists, and eradication is impossible given the commensal nature of these organisms.